 Ernesto Sparrelid
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 58 | 2025 | 251 | 9.820 |
Why?
| | Liver Neoplasms | 48 | 2025 | 786 | 8.910 |
Why?
| | Portal Vein | 28 | 2025 | 120 | 6.410 |
Why?
| | Liver Failure | 16 | 2025 | 94 | 5.310 |
Why?
| | Pancreatic Neoplasms | 28 | 2025 | 938 | 5.180 |
Why?
| | Bile Duct Neoplasms | 19 | 2025 | 124 | 4.730 |
Why?
| | Pancreatectomy | 25 | 2025 | 253 | 4.130 |
Why?
| | Cholangiocarcinoma | 14 | 2025 | 104 | 3.650 |
Why?
| | Carcinoma, Pancreatic Ductal | 12 | 2025 | 289 | 3.640 |
Why?
| | Colorectal Neoplasms | 20 | 2025 | 806 | 3.480 |
Why?
| | Embolization, Therapeutic | 8 | 2025 | 229 | 3.200 |
Why?
| | Adenocarcinoma, Mucinous | 4 | 2022 | 80 | 2.850 |
Why?
| | Liver | 26 | 2025 | 1943 | 2.590 |
Why?
| | Klatskin Tumor | 11 | 2025 | 15 | 2.030 |
Why?
| | Pancreaticoduodenectomy | 12 | 2025 | 164 | 1.980 |
Why?
| | Liver Regeneration | 8 | 2025 | 46 | 1.980 |
Why?
| | Postoperative Complications | 37 | 2025 | 2654 | 1.930 |
Why?
| | Carcinoma, Hepatocellular | 8 | 2024 | 362 | 1.710 |
Why?
| | Pancreatic Fistula | 9 | 2025 | 30 | 1.580 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2022 | 12 | 1.560 |
Why?
| | Retrospective Studies | 70 | 2025 | 15657 | 1.530 |
Why?
| | Bile Ducts, Intrahepatic | 7 | 2024 | 78 | 1.350 |
Why?
| | Biliary Tract Neoplasms | 4 | 2025 | 30 | 1.330 |
Why?
| | Biliary Tract Surgical Procedures | 4 | 2025 | 26 | 1.300 |
Why?
| | Neoadjuvant Therapy | 9 | 2025 | 404 | 1.290 |
Why?
| | Aged | 60 | 2025 | 23961 | 1.140 |
Why?
| | Humans | 145 | 2025 | 137585 | 1.020 |
Why?
| | Middle Aged | 66 | 2025 | 33479 | 1.010 |
Why?
| | Bone Marrow Transplantation | 15 | 2000 | 286 | 0.980 |
Why?
| | Prognosis | 21 | 2025 | 4030 | 0.940 |
Why?
| | Cysts | 1 | 2025 | 113 | 0.860 |
Why?
| | Gallbladder Neoplasms | 2 | 2023 | 23 | 0.850 |
Why?
| | Ligation | 12 | 2021 | 92 | 0.830 |
Why?
| | Liver Diseases | 3 | 2025 | 315 | 0.780 |
Why?
| | Sweden | 12 | 2025 | 101 | 0.750 |
Why?
| | Metastasectomy | 1 | 2021 | 20 | 0.690 |
Why?
| | Male | 66 | 2025 | 67762 | 0.680 |
Why?
| | Adult | 49 | 2025 | 37929 | 0.670 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2025 | 1692 | 0.670 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 306 | 0.660 |
Why?
| | Female | 65 | 2025 | 73304 | 0.640 |
Why?
| | Tomography, X-Ray Computed | 6 | 2025 | 2691 | 0.630 |
Why?
| | Robotic Surgical Procedures | 4 | 2025 | 130 | 0.630 |
Why?
| | Survival Rate | 16 | 2025 | 1972 | 0.610 |
Why?
| | Carcinoma | 1 | 2021 | 240 | 0.600 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2021 | 190 | 0.590 |
Why?
| | Liver Function Tests | 4 | 2022 | 114 | 0.550 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1313 | 0.550 |
Why?
| | Risk Factors | 24 | 2025 | 10388 | 0.530 |
Why?
| | Stem Cell Transplantation | 2 | 2015 | 176 | 0.510 |
Why?
| | Liver Transplantation | 4 | 2025 | 871 | 0.510 |
Why?
| | Laparoscopy | 4 | 2024 | 466 | 0.500 |
Why?
| | Hepatitis B virus | 1 | 2016 | 40 | 0.490 |
Why?
| | Adenoviridae Infections | 1 | 2015 | 17 | 0.480 |
Why?
| | Hypertrophy | 4 | 2025 | 133 | 0.480 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 806 | 0.470 |
Why?
| | Prospective Studies | 13 | 2025 | 7604 | 0.460 |
Why?
| | Adenoviridae | 1 | 2015 | 193 | 0.450 |
Why?
| | Mesenteric Veins | 2 | 2025 | 24 | 0.450 |
Why?
| | Cholangitis | 2 | 2025 | 21 | 0.450 |
Why?
| | Health Services Accessibility | 1 | 2021 | 986 | 0.430 |
Why?
| | Aged, 80 and over | 14 | 2025 | 7635 | 0.420 |
Why?
| | Liver Cirrhosis | 3 | 2025 | 316 | 0.420 |
Why?
| | Pancreatitis, Chronic | 2 | 2024 | 58 | 0.420 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2025 | 1079 | 0.420 |
Why?
| | Organ Size | 4 | 2025 | 477 | 0.420 |
Why?
| | Treatment Outcome | 20 | 2025 | 10811 | 0.410 |
Why?
| | Lymph Nodes | 5 | 2024 | 491 | 0.410 |
Why?
| | Lymphatic Metastasis | 2 | 2024 | 352 | 0.400 |
Why?
| | Adenocarcinoma | 3 | 2024 | 940 | 0.400 |
Why?
| | Scandinavian and Nordic Countries | 5 | 2025 | 13 | 0.390 |
Why?
| | Follow-Up Studies | 12 | 2025 | 5131 | 0.390 |
Why?
| | Leucovorin | 5 | 2025 | 81 | 0.380 |
Why?
| | Disease Outbreaks | 1 | 2015 | 395 | 0.380 |
Why?
| | Neoplasm Staging | 5 | 2025 | 1389 | 0.350 |
Why?
| | Pancreatitis | 2 | 2022 | 134 | 0.350 |
Why?
| | Margins of Excision | 3 | 2021 | 50 | 0.350 |
Why?
| | Magnetic Resonance Imaging | 7 | 2025 | 3566 | 0.340 |
Why?
| | Serum Albumin | 2 | 2022 | 150 | 0.340 |
Why?
| | Cholangitis, Sclerosing | 2 | 2021 | 75 | 0.330 |
Why?
| | Biliary Tract | 2 | 2021 | 17 | 0.320 |
Why?
| | Fluorouracil | 4 | 2025 | 208 | 0.320 |
Why?
| | Killer Cells, Natural | 2 | 2025 | 449 | 0.310 |
Why?
| | Vascular Surgical Procedures | 3 | 2025 | 303 | 0.290 |
Why?
| | Propensity Score | 3 | 2025 | 294 | 0.280 |
Why?
| | Radionuclide Imaging | 3 | 2022 | 118 | 0.270 |
Why?
| | Intention to Treat Analysis | 2 | 2024 | 73 | 0.270 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2024 | 98 | 0.260 |
Why?
| | Contrast Media | 4 | 2025 | 467 | 0.260 |
Why?
| | Indocyanine Green | 2 | 2023 | 24 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 900 | 0.250 |
Why?
| | T-Lymphocyte Subsets | 3 | 2024 | 417 | 0.250 |
Why?
| | Lymph Node Excision | 2 | 2024 | 171 | 0.250 |
Why?
| | Transplantation, Autologous | 4 | 2023 | 238 | 0.250 |
Why?
| | Survival Analysis | 5 | 2021 | 1325 | 0.240 |
Why?
| | Integrin alpha Chains | 1 | 2025 | 24 | 0.240 |
Why?
| | Quinolines | 2 | 2024 | 178 | 0.240 |
Why?
| | Hepatic Artery | 1 | 2025 | 62 | 0.240 |
Why?
| | Bacteremia | 5 | 2013 | 214 | 0.240 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2025 | 21 | 0.240 |
Why?
| | Hyperbilirubinemia | 1 | 2025 | 13 | 0.240 |
Why?
| | Digestive System Surgical Procedures | 2 | 2024 | 106 | 0.240 |
Why?
| | Ascites | 1 | 2025 | 46 | 0.230 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2025 | 52 | 0.230 |
Why?
| | Ablation Techniques | 2 | 2025 | 36 | 0.230 |
Why?
| | Gallbladder Diseases | 1 | 2024 | 12 | 0.230 |
Why?
| | Failure to Rescue, Health Care | 1 | 2024 | 5 | 0.230 |
Why?
| | CA-19-9 Antigen | 1 | 2024 | 22 | 0.230 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2025 | 77 | 0.220 |
Why?
| | Hyperamylasemia | 1 | 2024 | 4 | 0.220 |
Why?
| | Operative Time | 1 | 2024 | 145 | 0.220 |
Why?
| | Duodenal Neoplasms | 1 | 2024 | 23 | 0.210 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2024 | 30 | 0.210 |
Why?
| | Blood Loss, Surgical | 1 | 2024 | 101 | 0.210 |
Why?
| | Ampulla of Vater | 1 | 2024 | 42 | 0.210 |
Why?
| | Patient Outcome Assessment | 1 | 2024 | 131 | 0.210 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2023 | 64 | 0.210 |
Why?
| | Pancreas | 5 | 2024 | 329 | 0.210 |
Why?
| | Warfare | 1 | 2023 | 68 | 0.210 |
Why?
| | Registries | 4 | 2024 | 2035 | 0.210 |
Why?
| | Hyperemia | 1 | 2023 | 49 | 0.200 |
Why?
| | Delphi Technique | 1 | 2024 | 280 | 0.200 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 21 | 0.200 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2023 | 67 | 0.200 |
Why?
| | Antiviral Agents | 4 | 2015 | 744 | 0.200 |
Why?
| | Carcinoma, Papillary | 1 | 2023 | 81 | 0.190 |
Why?
| | Hemostatics | 1 | 2022 | 52 | 0.190 |
Why?
| | Antigens, CD | 1 | 2025 | 521 | 0.190 |
Why?
| | Europe | 4 | 2024 | 414 | 0.190 |
Why?
| | alpha 1-Antitrypsin | 1 | 2023 | 108 | 0.190 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2021 | 22 | 0.190 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 122 | 0.190 |
Why?
| | Hepatic Veins | 2 | 2022 | 33 | 0.180 |
Why?
| | Fibrinogen | 1 | 2022 | 168 | 0.180 |
Why?
| | Time Factors | 9 | 2025 | 6828 | 0.180 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2021 | 37 | 0.180 |
Why?
| | DNA, Viral | 3 | 2015 | 364 | 0.180 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1276 | 0.180 |
Why?
| | Pancreatic Cyst | 1 | 2021 | 60 | 0.170 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1509 | 0.170 |
Why?
| | Surgeons | 1 | 2025 | 297 | 0.170 |
Why?
| | Mycoses | 2 | 1998 | 79 | 0.170 |
Why?
| | Intraoperative Care | 1 | 2020 | 52 | 0.170 |
Why?
| | Camptothecin | 1 | 2021 | 116 | 0.170 |
Why?
| | Bevacizumab | 1 | 2021 | 138 | 0.170 |
Why?
| | Transplantation, Homologous | 8 | 2013 | 416 | 0.170 |
Why?
| | Cytomegalovirus Infections | 4 | 1998 | 192 | 0.170 |
Why?
| | Sarcopenia | 1 | 2021 | 83 | 0.160 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 752 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 889 | 0.160 |
Why?
| | Precancerous Conditions | 1 | 2021 | 169 | 0.160 |
Why?
| | Incidence | 8 | 2024 | 2804 | 0.160 |
Why?
| | Cytokines | 4 | 2025 | 2085 | 0.160 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 486 | 0.150 |
Why?
| | Neutropenia | 2 | 2013 | 146 | 0.150 |
Why?
| | Bacterial Infections | 2 | 1998 | 250 | 0.150 |
Why?
| | Neoplasm Grading | 1 | 2019 | 307 | 0.150 |
Why?
| | Receptors, KIR | 1 | 2019 | 98 | 0.150 |
Why?
| | Risk Assessment | 5 | 2025 | 3457 | 0.150 |
Why?
| | Hepatocyte Growth Factor | 1 | 2018 | 35 | 0.140 |
Why?
| | Adipose Tissue | 1 | 2022 | 635 | 0.140 |
Why?
| | Neoplasm Invasiveness | 1 | 2019 | 510 | 0.140 |
Why?
| | HLA Antigens | 1 | 2019 | 240 | 0.140 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 388 | 0.140 |
Why?
| | Epidermal Growth Factor | 1 | 2018 | 177 | 0.140 |
Why?
| | Autoimmune Diseases | 1 | 2021 | 460 | 0.140 |
Why?
| | Parainfluenza Virus 1, Human | 1 | 1997 | 3 | 0.140 |
Why?
| | Catheter Ablation | 1 | 2021 | 350 | 0.140 |
Why?
| | Respirovirus Infections | 1 | 1997 | 13 | 0.140 |
Why?
| | C-Reactive Protein | 1 | 2019 | 410 | 0.140 |
Why?
| | Influenza B virus | 1 | 1997 | 44 | 0.130 |
Why?
| | Thyrotropin | 3 | 2021 | 114 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 210 | 0.130 |
Why?
| | Curriculum | 1 | 2024 | 992 | 0.130 |
Why?
| | Th2 Cells | 2 | 1997 | 176 | 0.130 |
Why?
| | Graft Survival | 3 | 1998 | 535 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2023 | 617 | 0.130 |
Why?
| | Constriction, Pathologic | 1 | 2017 | 245 | 0.130 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2025 | 389 | 0.130 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1997 | 173 | 0.130 |
Why?
| | Virus Diseases | 2 | 2016 | 212 | 0.130 |
Why?
| | Ribavirin | 1 | 1997 | 91 | 0.130 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 1040 | 0.130 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1266 | 0.130 |
Why?
| | Multicenter Studies as Topic | 3 | 2022 | 310 | 0.130 |
Why?
| | Postoperative Period | 3 | 2023 | 342 | 0.130 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1587 | 0.130 |
Why?
| | Clinical Competence | 1 | 2024 | 1118 | 0.120 |
Why?
| | Cytosine | 1 | 2015 | 49 | 0.120 |
Why?
| | Logistic Models | 1 | 2021 | 2074 | 0.120 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1997 | 128 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 356 | 0.120 |
Why?
| | Hepatitis B | 1 | 2016 | 70 | 0.120 |
Why?
| | Gaucher Disease | 1 | 1995 | 6 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2018 | 545 | 0.120 |
Why?
| | Organophosphonates | 1 | 2015 | 93 | 0.120 |
Why?
| | Inflammation | 2 | 2022 | 2837 | 0.110 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 815 | 0.110 |
Why?
| | Opportunistic Infections | 1 | 1995 | 46 | 0.110 |
Why?
| | Sepsis | 2 | 2004 | 617 | 0.110 |
Why?
| | Interleukin-6 | 2 | 2018 | 778 | 0.110 |
Why?
| | Preoperative Period | 2 | 2025 | 129 | 0.110 |
Why?
| | Japan | 2 | 2025 | 115 | 0.110 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5778 | 0.110 |
Why?
| | Bilirubin | 2 | 2025 | 97 | 0.110 |
Why?
| | Insulin Resistance | 1 | 2022 | 1208 | 0.110 |
Why?
| | Fungemia | 1 | 2013 | 4 | 0.110 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2015 | 91 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 1040 | 0.110 |
Why?
| | Quality of Life | 5 | 2024 | 2892 | 0.110 |
Why?
| | Reoperation | 1 | 2016 | 573 | 0.110 |
Why?
| | Cholecystectomy | 2 | 2024 | 62 | 0.110 |
Why?
| | Amylases | 2 | 2024 | 17 | 0.100 |
Why?
| | Gadolinium DTPA | 2 | 2025 | 70 | 0.100 |
Why?
| | Bile Ducts | 2 | 2024 | 71 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2013 | 622 | 0.100 |
Why?
| | Graft Rejection | 1 | 1997 | 624 | 0.100 |
Why?
| | Graft vs Host Disease | 8 | 2000 | 252 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1639 | 0.100 |
Why?
| | Drainage | 2 | 2025 | 173 | 0.100 |
Why?
| | Phenotype | 4 | 2024 | 3196 | 0.100 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5472 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 1997 | 890 | 0.090 |
Why?
| | Phylogeny | 1 | 2015 | 904 | 0.090 |
Why?
| | Child, Preschool | 12 | 2013 | 11074 | 0.090 |
Why?
| | Influenza, Human | 1 | 1997 | 622 | 0.090 |
Why?
| | Lung Diseases, Interstitial | 1 | 1997 | 638 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2018 | 2833 | 0.080 |
Why?
| | Viridans Streptococci | 2 | 2013 | 6 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 2031 | 0.080 |
Why?
| | Obesity | 1 | 2022 | 2992 | 0.080 |
Why?
| | Lymphoproliferative Disorders | 1 | 2009 | 57 | 0.080 |
Why?
| | Heart Failure | 1 | 2022 | 2236 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 674 | 0.070 |
Why?
| | Herpesvirus 4, Human | 1 | 2009 | 166 | 0.070 |
Why?
| | Leukemia | 4 | 1998 | 240 | 0.070 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2009 | 98 | 0.070 |
Why?
| | Anti-Infective Agents | 3 | 2013 | 255 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2009 | 1062 | 0.070 |
Why?
| | Tumor Burden | 2 | 2021 | 309 | 0.070 |
Why?
| | Feasibility Studies | 2 | 2025 | 956 | 0.070 |
Why?
| | Cohort Studies | 3 | 2024 | 5742 | 0.070 |
Why?
| | Hematologic Diseases | 2 | 1998 | 62 | 0.070 |
Why?
| | Infant | 8 | 2013 | 9465 | 0.070 |
Why?
| | T-Lymphocytes | 3 | 2021 | 1996 | 0.060 |
Why?
| | Norway | 2 | 2016 | 43 | 0.060 |
Why?
| | Child | 11 | 2013 | 21935 | 0.060 |
Why?
| | Disease-Free Survival | 2 | 2025 | 686 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2021 | 1477 | 0.060 |
Why?
| | Conversion to Open Surgery | 1 | 2025 | 16 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 98 | 0.060 |
Why?
| | Neoplasm Metastasis | 2 | 2018 | 658 | 0.060 |
Why?
| | Histocompatibility Testing | 4 | 1998 | 126 | 0.060 |
Why?
| | Combined Modality Therapy | 2 | 2025 | 1236 | 0.060 |
Why?
| | Albumins | 1 | 2025 | 114 | 0.060 |
Why?
| | Capecitabine | 1 | 2024 | 45 | 0.050 |
Why?
| | Lactates | 1 | 2024 | 85 | 0.050 |
Why?
| | Israel | 1 | 2023 | 56 | 0.050 |
Why?
| | Adolescent | 10 | 2022 | 21513 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2025 | 179 | 0.050 |
Why?
| | Paclitaxel | 1 | 2025 | 230 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2023 | 14 | 0.050 |
Why?
| | Amphotericin B | 2 | 2013 | 31 | 0.050 |
Why?
| | Medical Futility | 1 | 2023 | 23 | 0.050 |
Why?
| | Interleukins | 1 | 2025 | 250 | 0.050 |
Why?
| | Keratin-19 | 1 | 2023 | 3 | 0.050 |
Why?
| | Candidiasis | 2 | 2013 | 56 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 554 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 104 | 0.050 |
Why?
| | Health Care Surveys | 1 | 2025 | 565 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 205 | 0.050 |
Why?
| | Hepatomegaly | 1 | 2022 | 4 | 0.050 |
Why?
| | Venous Thrombosis | 1 | 2025 | 190 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2023 | 135 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2025 | 480 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 126 | 0.050 |
Why?
| | Hepatocytes | 1 | 2023 | 220 | 0.050 |
Why?
| | Pancreaticojejunostomy | 1 | 2022 | 8 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 83 | 0.050 |
Why?
| | Acute Disease | 2 | 2022 | 1007 | 0.050 |
Why?
| | Ceramides | 1 | 2022 | 118 | 0.050 |
Why?
| | Abdomen | 1 | 2022 | 125 | 0.050 |
Why?
| | Regression Analysis | 1 | 2024 | 1024 | 0.050 |
Why?
| | Bismuth | 1 | 2021 | 1 | 0.050 |
Why?
| | Anemia, Aplastic | 3 | 1997 | 38 | 0.040 |
Why?
| | Consensus | 1 | 2024 | 683 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 324 | 0.040 |
Why?
| | Endoscopy | 1 | 2024 | 318 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 429 | 0.040 |
Why?
| | Population Surveillance | 1 | 2024 | 482 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2025 | 740 | 0.040 |
Why?
| | Clone Cells | 1 | 2020 | 265 | 0.040 |
Why?
| | Neutrophils | 3 | 2021 | 1238 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2020 | 224 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2021 | 233 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2020 | 166 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 284 | 0.040 |
Why?
| | Cytomegalovirus | 2 | 1997 | 157 | 0.040 |
Why?
| | Receptors, KIR2DL3 | 1 | 2019 | 9 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2023 | 746 | 0.040 |
Why?
| | Asia | 1 | 2019 | 71 | 0.040 |
Why?
| | South America | 1 | 2019 | 60 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2025 | 786 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 268 | 0.040 |
Why?
| | HLA-A Antigens | 1 | 1998 | 55 | 0.040 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1998 | 59 | 0.040 |
Why?
| | HLA-B Antigens | 1 | 1998 | 62 | 0.040 |
Why?
| | Immunologic Memory | 1 | 2020 | 353 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2004 | 558 | 0.040 |
Why?
| | North America | 1 | 2019 | 313 | 0.040 |
Why?
| | Aspirin | 1 | 2021 | 387 | 0.040 |
Why?
| | Hepatitis, Viral, Human | 1 | 1997 | 25 | 0.030 |
Why?
| | Palliative Care | 1 | 2024 | 758 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 1998 | 228 | 0.030 |
Why?
| | Viral Matrix Proteins | 1 | 1997 | 30 | 0.030 |
Why?
| | Preoperative Care | 1 | 2020 | 362 | 0.030 |
Why?
| | Patients | 1 | 2019 | 175 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1483 | 0.030 |
Why?
| | Iatrogenic Disease | 1 | 2017 | 67 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 377 | 0.030 |
Why?
| | Transplantation Conditioning | 1 | 1998 | 170 | 0.030 |
Why?
| | Metabolic Diseases | 2 | 1995 | 108 | 0.030 |
Why?
| | Ligands | 1 | 2019 | 664 | 0.030 |
Why?
| | Liver Failure, Acute | 1 | 1997 | 67 | 0.030 |
Why?
| | Pilot Projects | 1 | 2022 | 1710 | 0.030 |
Why?
| | Injections, Intravenous | 1 | 1997 | 206 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2021 | 1993 | 0.030 |
Why?
| | Young Adult | 3 | 2024 | 13209 | 0.030 |
Why?
| | Antigens, Viral | 1 | 1997 | 178 | 0.030 |
Why?
| | Ethanol | 1 | 2021 | 608 | 0.030 |
Why?
| | Prevalence | 1 | 2023 | 2734 | 0.030 |
Why?
| | Eye Neoplasms | 1 | 2016 | 18 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 660 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2024 | 2828 | 0.030 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2017 | 213 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1386 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1996 | 132 | 0.030 |
Why?
| | 4-Quinolones | 1 | 1995 | 2 | 0.030 |
Why?
| | Tomography | 1 | 1995 | 40 | 0.030 |
Why?
| | Splenectomy | 1 | 1995 | 62 | 0.030 |
Why?
| | Phosphoproteins | 1 | 1997 | 338 | 0.030 |
Why?
| | Wilms Tumor | 1 | 2016 | 86 | 0.030 |
Why?
| | Administration, Oral | 1 | 1997 | 816 | 0.030 |
Why?
| | Anthropometry | 1 | 1995 | 213 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 971 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1457 | 0.030 |
Why?
| | Fluconazole | 1 | 2013 | 19 | 0.030 |
Why?
| | Enterococcus | 1 | 2013 | 23 | 0.030 |
Why?
| | Ciprofloxacin | 1 | 2013 | 29 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2023 | 1724 | 0.030 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2013 | 46 | 0.030 |
Why?
| | Monocytes | 1 | 1996 | 563 | 0.030 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2013 | 70 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1991 | 0.020 |
Why?
| | Spleen | 1 | 1995 | 514 | 0.020 |
Why?
| | Radiography | 1 | 1995 | 822 | 0.020 |
Why?
| | Linear Models | 1 | 2015 | 849 | 0.020 |
Why?
| | Patient Safety | 1 | 2016 | 314 | 0.020 |
Why?
| | Hepatitis C | 1 | 1995 | 271 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2019 | 951 | 0.020 |
Why?
| | Streptococcal Infections | 1 | 2013 | 151 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3556 | 0.020 |
Why?
| | Biomarkers | 1 | 2023 | 4149 | 0.020 |
Why?
| | Antibodies, Monoclonal | 3 | 2009 | 1430 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2426 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 1996 | 879 | 0.020 |
Why?
| | Animals | 2 | 2023 | 36940 | 0.020 |
Why?
| | Membrane Proteins | 1 | 1996 | 1164 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 400 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 86 | 0.020 |
Why?
| | Melanoma | 1 | 2016 | 760 | 0.020 |
Why?
| | Foscarnet | 2 | 1998 | 19 | 0.020 |
Why?
| | Rituximab | 1 | 2009 | 176 | 0.020 |
Why?
| | Macrophages | 1 | 1996 | 1547 | 0.020 |
Why?
| | Apoptosis | 1 | 1997 | 2553 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2475 | 0.020 |
Why?
| | Viral Load | 1 | 2009 | 466 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2757 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2009 | 236 | 0.020 |
Why?
| | Bone Marrow | 2 | 1998 | 286 | 0.020 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 1998 | 122 | 0.020 |
Why?
| | Interleukin-1 | 2 | 2004 | 965 | 0.020 |
Why?
| | Tissue Donors | 2 | 2000 | 425 | 0.020 |
Why?
| | Mice | 1 | 2023 | 17787 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2004 | 268 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2004 | 4193 | 0.010 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2000 | 50 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2000 | 46 | 0.010 |
Why?
| | Transplantation Chimera | 1 | 2000 | 54 | 0.010 |
Why?
| | Age Factors | 2 | 1998 | 3295 | 0.010 |
Why?
| | Whole-Body Irradiation | 1 | 2000 | 78 | 0.010 |
Why?
| | Tissue and Organ Harvesting | 1 | 2000 | 70 | 0.010 |
Why?
| | Cadaver | 1 | 2000 | 296 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1242 | 0.010 |
Why?
| | Transplantation Immunology | 1 | 1998 | 34 | 0.010 |
Why?
| | Acyclovir | 1 | 1998 | 101 | 0.010 |
Why?
| | Ganciclovir | 1 | 1997 | 53 | 0.010 |
Why?
| | Leukemia, Myeloid | 1 | 1997 | 45 | 0.010 |
Why?
| | Leukocyte Count | 1 | 1997 | 329 | 0.010 |
Why?
| | Probability | 1 | 1997 | 304 | 0.010 |
Why?
| | Exotoxins | 1 | 1996 | 16 | 0.010 |
Why?
| | Streptococcus | 1 | 1996 | 28 | 0.010 |
Why?
| | Lymphokines | 1 | 1996 | 131 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 1996 | 159 | 0.010 |
Why?
| | CD3 Complex | 1 | 1996 | 106 | 0.010 |
Why?
| | Th1 Cells | 1 | 1996 | 143 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 253 | 0.010 |
Why?
| | Blood Platelets | 1 | 1998 | 408 | 0.010 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1997 | 289 | 0.010 |
Why?
| | Biopsy | 1 | 1997 | 1129 | 0.010 |
Why?
| | Anemia | 1 | 1995 | 170 | 0.010 |
Why?
| | Down-Regulation | 1 | 1996 | 657 | 0.010 |
Why?
| | Lipopolysaccharides | 1 | 1996 | 886 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 1996 | 1142 | 0.010 |
Why?
| | Liposomes | 1 | 1993 | 223 | 0.010 |
Why?
| | Neoplasms | 1 | 1993 | 2671 | 0.000 |
Why?
|
|
Sparrelid's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|